THE CARCINOEMIBRYONIC ANTIGEN (CEA) as first described by Gold and Freedman (1965) was believed to be a tumourassociated antigen arising in tumours and foetal tissue of entodermal origin. Further studies have indicated that CEA or CEA-like materials may be detected in, in addition to tissues of entodermal origin, a large variety of normal and neoplastic tissues, such as lung, breast (Moore et al., 1971; Laurence et al., 1972) urogenital tract (Hall et al., 1972; Neville et al., 1973) and erythrocyte membranes (Nery, Bullman and Barsoum, 1973; Neville and Laurence, 1974) .
It is also known that foetal-type antigens can be detected on both long-and short-term cultured melanoma cells (Macher et al., 1975; Jerry et al., 1976; V7iza, Phillips and Trejdosiewicz, 1975; Hersey et al., 1976 ) and tend to occur in greater density on long-term cultured cells (Hersey et al., 1976) . In the present study the possibility that the foetal antigens identified on melanoma cells were, in part, CEA was examined in short-and longterm cultures. Antisera to CEA were tested against melanoma cells by leucocyte-dependent cytotoxic-antibody assays (LDA). Immunoabsorption techniques were used to establish the specificity of the reactions. The results appear to indicate that CEA can be identified on some melanoma cells by these assays, and that this antigen may, therefore, have biological significance in tumour rejection.
MATERIALS AND METHODS

CEA antigen preparation
CEA was prepared from 288 g of the hepatic metastases of a carcinoma of the colon, as previously described (Extract IL, Hughes, 1975) . In brief, the tissue was extracted with 0-6 M perchloric acid, the extract neutralized with 1 N NaOH and concentrated to a volume of 15 ml by ultrafiltration through a UM-10 Diaflo filter (Amicon Corp., Lexington, Mass.). CEA was then obtained by sequentially chromatoCorrespondence to: Dr P. Hersey, Kainematsu MIemorial Institute, Sydney Hospital, Sydney, N.S.W., 2000, Australia. graphing the extract on (1) Sephadex G-100 at pH 7-2, (2) DEAE Sephadex at pH 7-2 using an increasing NaCl concentration gradient for elution, (3) Sepharose 6B at pH 7-2, (4) DEAE Sephadex at pH 4-6 using an increasing NaCl concentration gradient for elution and, finally, on Sepharose 6B at pH 4-5. At each fractionation step, fractions containing CEA were pooled, concentrated by ultrafiltration and tested by Ouchterlony double diffusion and immunoelectrophoresis, using an unabsorbed antiserum to perchloric acid extracts of colonic carcinoma and an antiserum recognizing both CEA and the so-called Ca-2 antigen which cross-reacts with CEA (Hughes, 1973 ). Fractions were also tested by electrophoresis in agarose and staining the patterns so obtained with Coomassie blue, the periodicacid-Schiff reaction for carbohydrate and toluidine blue stain for metachromasia. The pure preparation of CEA was freezedried, weighed and redissolved to give a protein concentration of 1-042%.
Antisera
(i) Rabbit anti-CEA serum.-An antiserum to CEA was produced in a rabbit by 4 injections over a 63-day period of a total of 1016 ,ug of a pure preparation of CEA isolated as previously described (Extract 4Ca, Hughes, 1975) from 546 g of colonic carcinoma tissue obtained from 23 patients. When tested by Ouchterlony double diffusion against concentrated perchloric-acid extracts of normal colon and colonic carcinoma, this antiserum recognized two antigens, one of which gave a reaction of complete immunological identity with the single antigen recognized by an antiserum to CEA obtained from Dr P. Gold, Montreal General Hospital. The second antigen recognized by the antiserum was the so-called Ca-2 antigen which has been shown to share at least one antigenic determinant with CEA, although it does not possess the antigenic determinant specific to CEA (Hughes, 1973 (Hughes, , 1975 . To render the antiserum specific for CEA, preparations of the Ca-2 antigen obtained during the fractionation of perchloric-acid extracts of colonic carcinoma were added to an aliquot of the antiserum until only the CEA antigen was recognized in extracts of colonic carcinoma and fractions of such extracts (antiserum anti-Ca-l-Ab, Hughes, 1975) . This absorbed antiserum was the anti-CEA serum used in the LDA assays to be described.
(ii) Melanoma antisera were selected from patients known to have high levels of antibody, as determined by 51Cr release LDA assays against melanoma cells. Two of the antisera, BN and MB, were from female patients, while AB was from a male patient. MB and AB sera were obtained 2-4 weeks after removal of a primary melanoma, while BN was taken from a patient with disseminated melanoma.
(iii) Serum SK was from a woman at the third trimester of her 5th pregnancy. Serum AE was from a multiparous woman about 20 years after her last pregnancy.
51Cr-release LDA assays
These were carried out essentially as described previously (Hersey et al., 1976) . Target cells used in the study were from the long-term melanoma cell line MM 200, which was obtained from Dr J. Pope of the Queensland Institute of Medical Research. Short-term melanoma cultures were from melanoma tissue obtained at surgery. Methods involved in preparing the specimens for the assay and of culture have been described (Hersey et al., 1976) . Titre of antiserum was taken as the last dilution giving greater than 5% 51Cr release above the baseline release from TCs in presence of effector cells alone.
Affinity chromatography of CEA antigen on concanavalin-A (Con-A) sepharose 4B 1 ml of Con-A Sepharose 4B containing 8 mg of Con-A (Pharmacia Ltd) was packed into a column constructed from a Mantoux syringe barrel and equilibrated in Hanks' balanced salt solution (HBSS, Commonwealth Serum Laboratories, Melbourne). The CEA antigen preparation (50 ,ul, 10 ,ug/ml) was applied to the column and incubated at room temperature for 60 min.-Any unbound material was then washed from the column with HBSS. A control column was prepared by addition of a similar quantity of an extract of intestine known to have negligible levels of CEA by radioimmunoassay. This was referred to as Con-A CEA-column.
Absorption of antisera
The rabbit anti-CEA serum prepared as above was absorbed on 1/3 volume pooled human platelets for 30 min at 37°C and then 1 h at 4°C to remove contaminating species antibodies. Any immune complexes were removed from the serum by centrifugation at 100,000 g for 90 min. The antiserum SK collected during pregnancy was absorbed on 1/4 volume of her husband's leucocytes and erythrocytes to remove any contaminating HLA antibodies which may have developed during her pregnancies.
Aliquots of both the rabbit anti-CEA serum and the pregnancy serum wN-ere absorbed on 1/3 volume of type AB human red blood cells. All sera Awere aliquotted and stored at -20°C before use.
Absorptioni of antisera on(CEA 400 ,ul of the serum samples wiere applied to the Con-A CEA column, prepared as above, and incubated at room temperature for 30 min. The unbound material was then eluted with 800 ,ul of HBSS for use in the assays. A second sample of each antiserum was absorbed in parallel on control columnns consisting of either Con-A alone or Con-A CEA-.
RESULTS
Purity of the CEA preparation
When the CEA antigen preparation was tested by Ouchterlony double diffusion and immunoelectrophoresis against the unabsorbed antiserum to perchloricacid extracts of colonic carcinoma, the antiserum recognizing both CEA and Ca-2 and the CEA antiserum, only a single precipitin line was observed in each case (see Fraction 2, Fig. 1 (Hughes, 1973) Fraction 2, Fig. 1 cell which extended to a titre of 1/1000. The reason for the low level of 51Cr release by the rabbit CEA antiserum is not entirely clear. In 51Cr-release assays of complement lysis of cells, the level of 51Cr release has been related to the antigenic density on the cell surface.
An alternative explanation which we favour would be that only a small proportion of 51Cr-labelled cells express CEA antigen at any one time due to different cells being in a different phase of the cell cycle.
Immunofluorescence studies on melanoma cells with melanoma antisera supports such a suggestion, in that with some antisera only 25-30% of cells were stained at any one time (Leong, Sutherland and Krementz, 1977) . The 51Cr release from this small proportion of cells would then appear small in relation to the 51Cr still present in viable intact cells.
The low release is clearly not due to weakness of the antiserum in that the titre extends to beyond 1/1000. This activity was completely removed after the antiserum had been passed over the Con-A CEA column. The pregnancy serum SK had a high level of cytotoxicity, with a titre of 1/1000. Absorption of this serum on the Con-A CEA column also almost completely removed the LDA activity against the melanoma cells. Absorption of either serum on the Con-A CEA-column or on human AB red cells did not alter the LDA activity to the melanoma cells. In Table I To investigate the possibility that some of the reactivity of melanoma antisera may be directed against CEA antigens, melanoma antisera from 3 patients were absorbed on the Con-A CEA column. The results of these studies, together with absorption studies on antiserum from a normal subject (AE) and the rabbit anti-Chang serum against Chang cells is shown in Table II This also applied to absorption of the rabbit anti-Chang serum, in that no alteration of the reactivity was seen against the control Chang cell. (Serum from the normal subject AE was shown in previous studies to be directed against foetal antigens on melanoma cells [Hersey et at., 1976] .) DISCUSSION The above results appear to indicate that some melanoma cells, in common with a number of other malignancies, express CEA or CEA-like antigens on their surface. They also indicated that foetal antigens shown on melanoma cells in previous studies may, in part, be CEA-like antigens. However, foetal antigens other than CEA also appear to be expressed on melanoma cells, in that absorption on CEA of an antiserum known from previous studies to react with foetal antigens on melanoma cells, did not remove the activity of this antiserum against melanoma cells (Hersey et al., 1976) .
The precise identity of the antigens on the melanoma cell surface reacting with the CEA antiserum has not been defined in this study, and it is possible that they are molecules sharing antigenic determinants with CEA, and hence are CEA-like antigens. To some extent, description of CEA-reactive antigens as 'CEA' or 'CEA-like' appears arbitrary, in that CEA antigens from most sources appear to be heterogeneous (Coligan et al., 1973; Harvey et al., 1976) . Studies to establish further the presence of CEA in melanoma cells by extraction procedures are in progress.
Before it can be accepted that CEA antigen is present on some melanoma cells, the possibility must be excluded that the reactivity of the anti-CEA serum may have been due to contaminating antibodies in the antiserum. This appears unlikely, in view of the rigorous method used in preparing the antigen and the extensive absorption procedures carried out on the antiserum raised against this antigen. Antigen was prepared from a metastasis of the colon in liver by established methods (Hughes, 1973 (Hughes, , 1975 and gave a single precipitation line with the unabsorbed rabbit antiserum by immunoelectrophoresis and double diffusion in agar. These results conform to the criteria for CEA suggested by Terry et al. (1974) . Absorption of the rabbit antiserum to CEA and the pregnancy antiserum, on an affinity column formed by coupling the CEA antigen to Con-A sepharose, removed the LDA activity to the melanoma cells. These results further indicated that the reactions were specific for CEA on the cell surface. Similar absorption procedures on rabbit anti-Chang serum did not remove the activity against the Chang cell, and absorption of several melanoma antisera did not remove the activity against melanoma cells which substantiated the specificity of the absorption procedure for CEA.
To our knowledge, there have been no previous descriptions of LDA activity against CEA antigens. Antibody-dependent killing of tumour cells is believed to be of possible importance in tumour rejection (Lamon et al., 1972; O'Toole et al., 1973; and it would therefore appear feasible that CEA antigens may provide a target antigen for the immune defences against tumour growth. In the present studies however, we have not been able to detect antibodies to CEA antigens in several melanoma sera. Our failure to detect LDA may reflect an absence of an IgG antibody response in these patients or, alternatively, may result from absorption of the antibody by circulating tumour antigens. We have previously reported that absorption of LDA by melanoma antigens appears to be a common finding in patieints with disseminated melanoma (Murray, McCarthy and Hersey, 1977) .
Previous studies on antibody to CEA in the sera of tumour-bearing subjects have also shown a low incidence of antibody. Gold (1967) reported that IgM anti-CEA antibodies could be detected in approximately 70%O of patients with non-metastatic digestive-system cancers, but subsequent study showed that many of these reactions were due to anti-A isoantibodies, and the true incidence of antibody to CEA may be much lower than this (Gold, Freedman and Gold, 1972) . This also applied to the detection of CEA antibodies in sera from women during pregnancy, and the true incidence of CEA antibodies in pregnancy may be much lower than the figure of 7000 initially reported by Gold (1967) . In our present study, 5/15 women with pregnancies have shown reactivity to the melanoma target cell but we are unable to say without more extensive absorption studies whether this activity is due to anti-CEA antibodies in the sera.
Quite apart from the possible biological importance of CEA on melanoma cells, the present findings indicate that the application of assays for the detection of CEA antigens in melanoma sera may be of value in monitoring disease activity in melanoma patients, as has been described for a large variety of other tumours (Neville and Laurence, 1974) . Studies to determine whether this is so are in progress.
